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Abstract 
Background 
Since the clinical application of venous conduits in surgical myocardial 
revascularization, coronary artery bypass grafting has become a standard treatment for 
intractable angina due to coronary artery occlusive disease. However, the long-term 
success of this intervention was restricted by late vein graft occlusion. The 10-year 
patency rate of saphenous vein grafts remains somewhat less than 50%, which 
necessitates the continued research into its underlying pathology and the further 
development of therapeutic interventions aiming at preventing vein graft failure. It has 
been shown that neointimal hyperplasia attributing to vascular smooth muscle cell 
(VSMC) migration and proliferation with excessive extracellular matrix production 
plays a central role in vein graft restenosis. Some novel vascular markers and 
therapeutic strategies, such as pharmacologic therapy and gene therapy, have emerged 
over the past decade. The objective of this study is to determine the postoperative 
osteopontin (OPN) associated with matrix metalloproteinases (MMPs) induction in 
vein graft in vivo and to explore the potential correlation between vein graft intimal 
hyperplasia and OPN expression. Moreover, the therapeutic effects of adenoviruses-
mediated gene delivery on neointima formation were also investigated. 
Methods 
A well-established porcine model of carotid artery-saphenous vein interposition 
grafting was used. Female landrace pigs weighing 35-40kg were randomly divided 
into several groups according to their required postoperative surviving durations. 
Each pig underwent bilateral saphenous vein implantation into carotid artery system 
using end-to-end anastomoses under general anaesthesia. In the gene therapy study, all 
saphenous vein grafts were treated with adenoviruses-mediated gene (or a control 
gene) prior to the above-mentioned grafting procedure. At 1 week, 2 weeks, I month 
and 3 months after operation, the vein grafts were harvested. All the patent venous 
grafts received further immunohistochemistry investigation, western blot assay, and 
quantitative morphometric analyses on vascular remodeling. 
Results 
i 
In this porcine model, the OPN expression in the intima of the vein grafts peaked 
nearly 9-fold at the end of the first postoperative week comparing with the baseline 
levels. The OPN expression appeared more in the media than in the intima after 
second postoperative week. Meanwhile, nearly 15-fold and 20-fold increase in both 
pro-MMP-2 and active-MMP-2 productions were found in the vein grafts over the 
same time period, which significantly correlated with OPN overexpression. These 
changes were consistent with the temporary increase in V S M C migration and 
proliferation within the intima and media, while the later was demonstrated by the 
percentage of proliferating cell nuclear antigen (PCNA) positively stained nuclei at 
different time points. On a separate note, we demonstrated that luminal delivery of 
adenoviruses-mediated Nogo-B gene to porcine saphenous veins could evoke 
sustained protective effects as reflected by the significant reduction of the intimal area 
and the intima:media ratio. 
Conclusions 
The induction of OPN in the vein grafts and its associated MMP-2 production may 
play an important role in the development of VSMC migration, proliferation and 
intimal hyperplasia in this clinical relevant in vivo porcine model. Moreover, Nogo-B 
overexpression using an adenoviral gene transfer vector can remarkably reduce 
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1. Saphenous Vein Graft Patency after Coronary Artery Bypass Grafting 
Prevalence 
Coronary artery disease is now the most common cause of death and a substantial 
source of chronic disability and healthcare costs worldwide. i’2 The therapeutic options 
for patients with multivessel coronary artery disease consist of medical therapy, 
percutaneous coronary intervention, and coronary artery bypass grafting (CABG).^ 
Disquiet about the clinical outcome with drug eluting stents has recently been 
superseded by concerns about the increased risk of late thrombosis and its associated 
relatively high mortality.'^ The apparent less-ideal prospect of drug-eluting stents 
resulted in even stronger interests in the better long-term results that likely achievable 
through surgical myocardial revascularization, namely CABG (Figure 1)^. 
V..i" Gmfts 
Figure 1. Coronary artery bypass grafting (from 
www.mmphealthcare.com/cat/images) 
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More than 800,000 patients may undergo CABG each year worldwide, while 
about 350,000 cases were performed annually in the U.S. alone.^ This signifies the 
utmost importance of mid- and long-term graft patency following CABG, which is a 
key predictor of many clinical outcome endpoints such as survival^ and postoperative 
quality of life. 
The choice of conduits 
In late 1960s, there were already reports of clinical application of internal 
mammary artery (IMA) and saphenous vein (SV) bypass grafts for occlusive coronary 
artery disease?�However , comparative observations on the IMA and SV grafts were 
not available until early 1980s which suggested the higher patency rate of IMA grafts. 
Retrospective analysis in large series of CABG cases documented improved late 
patency rate as well as absence of degenerative or atherosclerotic changes with the 
use of the IMA grafts, which resulted in an improved survival and much greater 
freedom from coronary events7 
The excellent patency rates achieved by the use of left internal mammary artery 
(LIMA) are well described, while searching for the second-best coronary bypass graft 
conduit has remained as a subject of debate for decades. The benefit of additional 
arterial conduits was proposed by Lytle and colleagues with their long-term follow-up 
data in favor of bilateral internal mammary arterial grafts.^ However, there are several 
technical concerns relating to the use of right internal mammary artery (RIMA) and 
there are also considerable risks including wound-related complications especially in 
patients with diabetes, obesity, or chronic obstructive pulmonary disease.^ '® Thus, 
some surgeons have turned their attention to the use of radial artery as a graft conduit 
that might have better patency than the saphenous vein grafts and could be easier to 
harvest when comparing with the RIMA grafts. 
After initial described in 1973 by Carpentier et al, the wide application of radial 
artery during CABG was soon abandoned mainly due to inadequate early 
postoperative angiographic findings. Nevertheless, improvements in graft harvesting 
techniques, avoidance of mechanical dilation, new preservation methods, and the use 
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of postoperative calcium channel blocker therapy to prevent early vasospasm led to a 
resurgence in the use of the radial artery in the 1990s.^ Whilst the viability of routine 
use of radial artery, with either gastroepiploic or inferior epigastric artery, and their 
long-term patency is still controversial and need further investigations. 
Though arteriosclerosis is rarely developed in IMA, which partially explains the 
conduit's excellent long-term patency record, they may still fail when bypassing 
coronary arteries with important competitive flow.'^ Other arterial grafts especially 
the radial artery^^have their susceptibility to spasm which might lead to graft atrophy 
and occlusion, n Some reports indicated that less-than-severe proximal right coronary 
artery stenosis may strongly decrease the patency rate of its bypass graft." Another 
randomized trial by Desai et al. also found that the patency of radial artery grafts 
positively related to the severity of native-vessel stenosis. Hence, they are 
preferentially used on target vessels with high-grade lesions.^^ 
To date, in addition to the IMA grafts, the SV remains the preferred conduit 
grafted to the branches of the right coronary artery, circumflex or diagonal vessels 
during CABG The LIMA to left anterior descending artery (LAD) graft is probably 
the most reliable treatment for coronary disease, and the standard CABG operation 
nowadays definitely involves this type of graft in combination of vein grafts to the 
other coronary vessels (Figure 2).'® In emergency situations, some surgeons may 
prefer the SV as a sole conduit because it can be harvested rapidly and is less 
disturbed by the perioperative pharmaceutical interventions. Some surgeons may use 
SV for isolated lesions in patients who require aortic or mitral valve surgery, while 
others may choose SV for patients with poor left ventricular function in view of their 
reduced life expectancy/ Furthermore, due to the evidence that recurrence of 
symptoms and graft disease are more prevalent in younger patients, and the 
atherosclerosis changes in IMAs can develop in the elderly patients, the use of the SV 




Figure 2. The use of LIMA and saphenous vein grafts in CABG. 
(from www.lahey.org/.../CADHeartImage) 
Comparisons in patency rate among different conduits 
Aorta-to-coronary saphenous vein grafts, the most widely used type of bypass 
graft, have historically had an occlusion rate of 10% to 15% within a year after 
surgery. Beyond 5 years after surgery, graft atherosclerosis develops in substantial 
numbers of saphenous vein grafts, and progressive graft failure occurs so that by 10 
years after CABG, less than 60% of grafts are still patent although half of them may 
have angiography evidence of atherosclerosis. By 20 years after surgery, the rate of 
graft patency appears to be only 20% to 25%.^®''"^(Figure 3) 
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Figure 3. Long-term vein graft patency^'" 
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Fitzgibbon and colleagues reported their angiographic data of 5,065 grafts over a 
25-year follow-up period from 1969 to 1994 which showed that vein graft patency 
was 88% at 1 month, 81% at 1 year, 75% at 5 years and 50% at 15 y e a r s . S u c h 
findings also correlated with clinical prognosis, specifically reflected by the 
reoperation rate and the survival” 
In another study involving 1402 symptomatic patients operated on between 1977 
and 1999 by Buxton and associates from Melbourne, the vein graft patency was 78% 
at 1 year, 78% at 5 years, 60% at 10 years, and 50% at 15 years; and a young age 
(p<0.001), an ejection fraction<30% (p<0.047), small coronary artery diameter 
(p<0.001), large conduit diameter (p=0.001)，and the target coronary artery (lowest 
patency in the right coronary and maximum patency in the left anterior descending 
artery territory; p=0.002) significantly affected graft patency. The authors concluded 
that the best results were obtained in older patients with good left ventricular function; 
while large-caliber arteries on the left coronary system, when grafted with a 
small-diameter vein, were associated with the best outcome. 
Goldman and co-workers further proved the above findings by showing their 
patency for SV grafts at 10 years was 61% compared with 85% for IMA grafts 
(p<0.001).5 However, if a SV or IMA graft was patent at 1 week, that graft had a 68% 
and 88% chance of being patent at 10 years respectively. They emphasized that the 
recipient vessel size was a significant predictor of graft patency, SV graft patency was 
88% in vessels > 2 mm in diameter versus 55% in vessels less than 2 mm in diameter 
(p<(X001).5 
Sabik et al from the Cleveland Clinic compared the graft patency rates in 4,333 
patients with 2,121 IMA grafts and 8,733 SV grafts.' ' They found that the 1-，5-，and 
10-year patency was 93%, 88%, and 90% for IMA grafts and 78%, 65% and 57% for 
SV grafts, respectively. 11 Nevertheless, when bypassing right coronary arteries with 
less than 70% stenosis, saphenous veins might be a better choice since it might be less 
affected by the native coronary artery competitive flow.'' 
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Prospective randomized trials about vein graft patency 
A prospective randomized study conducted by Buxton et al indicated no 
significant difference in patency rates among the RIMA, radial artery and SV grafts 5 
years after CABG'^ Another randomized trial comparing the radial artery with the 
free RIMA (if age<70 years) or with SV (if a g e � 7 0 years) when grafted onto the 
largest target other than the LAD revealed the overall patency of the in-situ internal 
thoracic artery grafts and free arterial grafts was 95.5% and 91.4% at 5 years, 
respectively, whilst the SV graft patency rate was 83%.'^ Collins and colleagues from 
London demonstrated that 98.3% radial artery grafts and 86.4% of SV grafts were 
patent at 5 years after grafted to a stenosed branch of the native left circumflex 
coronary artery (p=0.04). 
Recently, one of the largest randomized clinical phase III trail - PREVENT IV 
evaluated the vein graft failure (defined as > or =75% vein graft stenosis) rate 12-18 
months after CABG - about 28.5% in the edifoligide gene therapy group and 29.7% 
in the placebo group - most of which were occluded�8 Such a lower-than-expected 
1-year vein graft patency rate further emphasis the necessity of exploring the 
mechanisms involved and developing therapeutic strategies to prevent vein graft 
failure. 
Table 1 summarizes the SV graft patency rates in different clinical studies. 
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Table 1. Saphenous vein graft patency 
Author Year Grafts Patency (%) 
assessed 1-year 5-year 10-year 15-year 
Fitzgibbon et al.^^ 1996 5065 81 75 N.A. 50 
Shah et al^^ 2003 3715 78 78 60 50 
Goldman et ai^ 2004 1074(patients) 84 69(6-year) 61 N.A. 
Sabik 3rd et a / ." 2005 8733 78 65 57 N.A. 
Haywarde/a/.*'^ 2007 662 N.A. 83 N.A. N.A. 
Collins et al.*^ 2008 44 N.A 86.4 N.A N.A 
P R E V E N T IV*i8 2005 1829(patients) 71 N.A N.A N.A 
*Randomized controlled trials. 
Drawbacks of redo surgery or intervention 
About 4% of patients by 5 years, 19% of patients by 10 years, and 31% of 
patients by 12 years after initial CABG may require further revascularization, either 
redo bypass surgery or percutaneous intervention, to alleviate symptoms and treat 
graft occlusion. 19,20 As compared with initial surgery, reoperation carries a higher 
mortality rate (3%-7%) with a higher rate of perioperative myocardial infarction 
(4%-11.5%), as well as less complete relief of angina and further reduction in 
saphenous vein graft patency�9 Coronary atheroembolism from diseased vein grafts 
has been noted to be a major cause of the morbidity and mortality associated with 
reoperation. i5’2i’22 
Percutaneous treatments for vein graft disease continue to be hindered, despite 
recent adjunctive therapies, by a high periprocedural morbidity resulting from distal 
embolization of atherothrombotic debris with subsequently lower event-free survival 
due to frequent restenosis at the treated lesion site?" '^^ ^ 
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2. Mechanism of Vein Graft Failure and Therapeutic Strategies 
Evaluation of the saphenous vein grafts used in CABG has had a long history, and 
began in response to the high graft failure rate. First of all, the cause of early vein 
graft failure within the first postoperative week may stem from thrombosis inside the 
vein graft caused by a combination of structural and physiologic alterations in the 
vessel wall. Secondly, neointimal hyperplasia, defined as the accumulation of vascular 
smooth muscle cells (VSMC) and extracellular matrix in the intimal compartment of 
the vein, is the major disease process in venous grafts within the first year after bypass 
surgery. Thirdly, superimposed on neointimal formation is atherogenesis which 
ultimately leads to plaque rupture and graft occlusion beyond one year 
postoperatively (Figure 4).i9’26’27 Thus，early thrombosis and neointimal hyperplasia 
with consequent atherosclerosis are long thought to be the primary causes of graft 
failure and the three major pathogenesis of vein graft disease. 
Nevertheless, apart from antiplatelet^^ and lipid lowering�； therapy, no 
intervention has hitherto proved clinically effective in preventing vein graft failure.^® 
The purpose of this chapter is to review the pathogenesis and the preventive strategies, 
both established and experimental, for vein graft disease which include external stents 
or sheaths, as well as pharmacologic therapy; while gene therapy would be discussed 
later in Chapter 4. 
Ungrafted vem 飞 
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Figure 4. Saphenous vein graft disease (From Wan et al. Novel strategies for the prevention of vein 





Within the first month after bypass grafting surgery, the principal underlying 
mechanism in vein graft failure is thrombosis, caused by arterialization of the vein 
grafts attributing to the combined effects of altered flow dynamics, alterations in the 
vessel wall and changes in blood rheology.'^'^' 
During CABG, the harvesting and manipulating procedures of vein grafts 
inevitably predispose prominent endothelial cell loss associated with medial damage, 
especially due to the high pressure distension and the ischemia period.^^ This will 
results in the accumulation of fibrin on the luminal surface, the adherence of platelets 
and neutrophils, with a reduction in tissue plasminogen activator (tPA) production.]] 
Extrinsic coagulation cascade will also be activated by tissue factor expressed in the 
exposed subendothelium.^^ In addition, the inherent antithrombotic properties of veins 
are comparatively weak. The low fluid shear stress in grafted venous conduits, as 
compared with arteries, reduces the shear-dependent release of potent inhibitors of 
platelet activation, such as tPA, nitric oxide (NO) and prostacyclin.^'^ Another 
anticoagulant proteoglycan molecule, heparan sulfate, is less prominent in the media 
and the poorly developed internal elastic lamina of veins as compared with arteries? i 
Furthermore, in contrast to the thrombin-mediated vasorelaxation that occurs in 
internal mammary arteries, the predominant vasomotor response to thrombin is a 
constrictor one in saphenous veins. 
Combined with marked perioperative elevation of plasma fibrinogen and 
expressed tissue factor initiated by cardiopulmonary bypass,^^'^^ all these factors 
contribute to the rapidly platelet activation with magnified responses following 
venoarterial grafting, which subsequently leading to thrombosis and early graft 
failure. 
Neointimal hyperplasia 
Intimal hyperplasia occurs physiologically at closure of the ductus arteriosus,^^ as 
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well as pathologically in a variety of disease settings such as atherosclerosis, 
angioplasty, vein grafting surgery, arteriovenous fistulae formation and transplantation. 
On a basic level, intimal hyperplasia is defined as a process that involves continued 
migration and proliferation of VSMC into the intima compartment, often associated 
with deposition of extracellular matrix. It is the major disease process in venous 
grafts between 1 month and 1 year after vein graft implantation. 
It has been strongly suggested that neointimal hyperplasia attributes to extensive 
O Q 
endothelial denudation and destruction related with vigorous luminal distension 
during surgery, damage at surgical anastamoses, and continued physical trauma under 
arterial conditions.'^ Furthermore, arterial tangential pressure (a force encountered 
transverse to the arterial wall) as well as shear stress (which encountered 
longitudinally to the vessel wall) have also been implicated in the development of 
neointimal hyperplasia. The acute, pronounced increase in wall stress incurred by 
saphenous vein grafts on exposure to arterial pressures significantly upregulates vein 
graft intimal receptors for basic fibroblast growth factor (bFGF), which is a potent 
vascular VSMC mitogen released from damaged endothelial and VSMC;^^ on the 
other hand, the reduction in shear stress increases the shear-regulated production of a 
number of potent mitogens, including bFGF, platelet derived growth factor (PDGF), 
and endothelin 1 (ET-1), and attenuates the production of growth inhibitors such as 
transforming growth factor-P (TGF-p) and NO, thus shifting the balance toward 
smooth muscle cell proliferation and intimal hyperp las i a .^Al though the association 
between low shear stress and neointimal hyperplasia is well documented in vein 
grafts，34 it has been suggested that high shear stresses are also associated with 
neointimal hyperplasia ,� 
As such, medial VSMC proliferate initially in response to a number of growth 
factors, adhesion molecules and cytokines released from platelets and from activated 
endothelial cells and macrophages [i.e. PDGF, vascular cell adhesion molecule 
(VCAM), intercellular adhesion molecule (ICAM) cyclin-dependent kinases (Cdks), 
and E2F]. This is followed by migration of VSMC into the intima, with subsequent 
further proliferation. More recent evidence from a porcine model of saphenous vein 
1 0 
grafting indicates an additional mechanism for graft neointima formation involving 
perivascular fibroblasts. These fibroblasts translocate through the media of newly 
placed vein grafts and differentiate into myofibroblasts, acquiring a-smooth muscle 
actin.4i It is also noteworthy that the synthesis and deposition of extracellular matrix 
by activated VSMC leads to a progressive increase in intimal fibrosis and a reduction 
in cellularity.3i’34 There is now accumulating evidence that matrix metalloproteinases 
(MMPs), the physiological mediators of matrix deposition and degradation, play an 
important role in the development of neointimal hyperplasia following arterial 
bypass.27 
Subsequently, neointimal hyperplasia represents the foundation for later 
development of graft atheroma, possibly through accelerated lipid accumulation and 
monocyte transmigration."^^ The extensive intimal hyperplasia throughout the length 
of a vein graft as a nidus may effectively create a diffuse atherosclerosis-prone region. 
Atherosclerosis 
Since neointimal hyperplasia is considered as a nidus for atheroma formation, the 
accelerated, cholesterol-driven atherogenesis becomes predominant process 
underlying the attrition of saphenous vein grafts and the eventual recurrence of 
ischemic symptoms beyond the first year after bypass surgery. 
Although the progression of native vessel coronary disease is also important in 
symptom recurrence, angiographic studies indicate that the culprit lesion in 70%-85% 
of cases is an atherosclerotic vein graft stenosis, often with superimposed thrombus, 
among patients who present with unstable angina, non-Q-wave myocardial infarction, 
or Q-wave myocardial infarction after previous bypass surgery."^ '^"^ 
Necropsy studies have found evidence of atheromatous plaques as early as 1 year 
after CABG»45’46 but hemodynamically important stenoses resulting in recurrent 
symptoms rarely occur before 3 years after grafting, and the clinical impact of vein 
graft atheroma increases markedly after 5 to 7 y e a r s , l e a d i n g to occlusion rates of 
30% to 40% 10 to 12 years after surgery. This is especially common in patients with 
hyperlipidemia.45，48’50 
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Different from native vessel disease, the atherosclerotic process in saphenous vein 
graft progresses rapidly, which might attribute to chronic endothelial cell injury and 
dysftinction33，5i associated with the up regulation of adhesion molecules.^^'^^ The lipid 
CO 
handling of saphenous veins also relatively proatherogenic, with slow lipolysis, 
more active lipid synthesis, and higher lipid uptake，。than in native coronary arteries. 
Morphologically, vein graft atherosclerosis tends to be diffuse, concentric, and friable 
with a poorly developed or absent fibrous cap and little evidence of 
calcification，45’46’48’49 whereas histologically, vein graft atheroma contains more foam 
cells and inflammatory cells, including multinucleate giant cells.49 Subsequently, 
advanced atherosclerotic plaque formation would frequently progress to late graft 
thrombosis in old, degenerated vein grafts, resulting in recurrent myocardial 
ischemia.55 
2.2 Therapeutic strategies 
External Dacron stents, biodegradable sheaths and fibrin glues 
Animal studies demonstrated that arterial pressure induces overdistension of the 
thin-walled vein grafts which might be one principal cause promoting intimal 
hyperplasia followed by atherosclerosis, and that prevention of this overdistension 
with extravascular support ameliorates the arterialization process with more favorable 
patency.56 In a porcine model, placement of a porous, non-restrictive, external, 
polyester Dacron stent around saphenous vein-carotid interposition graft significantly 
reduced neointima formation and total wall thickness at both 1 and 6 months after 
implantation.57’58 Loose-fitting and macroporous is proved to be crucial in order to 
prevent neointimal thickening by the external polyester s t e n t , w h e r e a s loose fitting 
polytetrafiuoroethylene (PTFE) microporous stents not only promote neointimal and 
medial thickening, but also prevent microvessel formation (Figure 
1 2 
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Figure 5. Effect of the external Dacron stent. A loose fitting Dacron sheath or stent (upper left panel) 
was placed around a saphenous vein into a carotid artery interposition graft (upper right panel). After 1 
month, the graft was excised and studied histologically. As shown (lower left panel), there is a marked 
increase in graft size and neointima formation (the layer between the internal elastic lamina, lEL, and 
the lumen) compared to the original ungrafted saphenous vein (inset). It is this thickening that is the 
basis of vein graft failure. The graft fitted with the external stent, however, shows a profound reduction 
of graft thickening (small arrow lEL, large arrow external elastic lamina, EEL) and a complete 
inhibition of the neointima. (From Wan et al. Novel strategies for the prevention of vein graft disease. 
In: He GW, ed. Arterial grafting for coronary artery bypass surgery. 2nd Ed. Springer, 2006. p.303-10) 
Since the blocking mechanism happens within the first month after implantation, 
long-term support with a prosthetic sheath may not be necessary. Thus, an external 
polyglactin sheath which is hydrolyzed by macrophages between 60 and 90 days has 
been studied^^'^^ and found to reduce porcine vein graft thickening at 1 month,^^ 
which persisted for 6 months，� The main mode of action of the sheath is to promote 
angiogenesis and therefore prevention of graft hypoxia, indicated by the featured 
presence of a microvessel rich adventitia in the space between the graft and the 
stent.60-63 
Another in vitro closed-loop autologous blood perfusion model of human vein 
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graft made by Stooker and colleagues described benefits from perivenous support to 
prevent complete de-endothelialization and severe disruption of the circular muscle 
layer of the media after 60 minutes of perfusion. The perivenous supported grafts 
showed complete regeneration of the endothelial layer, a more gradual adaptation to 
arterial pressure and a more physiologic medial thickening or arterialization ensues 
compared with the nonsupported grafts. With no doubt, prevention of the injury in the 
first hour will have a favorable effect on graft wall integrity and, as a consequence, on 
patency in human vein grafts.^^ 
The other extravascular support strategy has been that of perivenous application 
of fibrin glue, which has been demonstrated to reduce endothelial and VSMC damage 
within the first hour of exposing to arterial pressure in an isolated human saphenous 
vein ex vivo model by Stooker et al，* It was reasoned that fibrin might be one of the 
most potent angiogenic factors known.^^'^^ Commercially available fibrin glue is a 
two-component fibrin sealant derived from human plasma, which mostly used to 
achieve hemostasis or seal tissue in the clinical setting. Nevertheless, one study on 
time-dependent effects of perivenous application of fibrin glue on medial thickening 
in porcine saphenous vein grafts by our team revealed that there was no inhibitory 
effect on saphenous vein graft thickening in vivo within one month by placement of 
fibrin glue. On the contrary, it may even promote the process when assessed at 4 
months, possibly through differential, time-dependent effects on VSMC proliferation 
and inflammation.^^ Therefore, further investigation is warranted to elucidate the 




Antiplatelet therapy and anticoagulants have been administered postoperatively 
based on the stated assumption of mechanism. Available data indicate that aspirin is 
effective in improving vein graft patency only if commenced no later than one day 
after surgery.^^'^^ In a series studies by Goldman and colleagues?® from 1980s to 
14 
1990s showed: by 7 to 10 days after surgery, 6%-8% of vein grafts occlude when 
patients were treated with aspirin, 325mg/d, compared with 15% when patients were 
given placebo; while the time point to initiate aspirin could be 6 hours after bypass 
surgery, rather than 12 hours before surgery, with the benefit of reducing bleeding 
complications. However, in patent vein grafts at 7 to 10 days, aspirin given for 1 year 
did not significantly reduce the 1 -year occlusion rate compared with placebo, whilst 
for vein grafts patent at 1 year, aspirin given for 3 years did not have significant 
effects on reducing the 3-year occlusion rate compared with p l acebo /� 
Dipyridamole transiently but significantly increased cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in 
human venous and arterial smooth muscle cells in a time- and dose-dependent manner. 
This consequently caused an enrichment of cells in GO/Gl and a corresponding 
reduction of cells in S phase, which correlated with inhibition of proliferation in both 
cell types in a study by Zhuplatov SB and colleagues.^' 
Several studies, including the CAB ADAS trial (prevention of Coronary Artery 
Bypass graft occlusion by Aspirin, Dipyridamole and Acenocoumarol/ 
phenoprocoumon Study) have shown that addition of dipyridamole to aspirin is no 
more effective than aspirin alone in maintaining graft patency;^^ Similarly, in a 
meta-analysis of 17 trials/^ aspirin strongly influenced graft occlusion, but 
dipyridamole provided no additional benefit. 
Ratnatunga and coworkers?* studied 294 patients 3 months after CABG and 
observed that 325mg of aspirin markedly suppressed in vitro shear-induced platelet 
activation involving thrombin generation, whereas 75mg of aspirin was associated 
with significant preservation of shear-induced platelet hyperreactivity. 
Other antiplatelet agents 
Indobufen，75，76 ticlopidine/^'^^ as well as clopidogrel have been demonstrated 
about comparable effect, even though ticlopidine may cause fatal thrombocytopenic 
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purpura or neutropenia. ’ Clopidogrel is an analog of ticlopidine that is safer. A 
randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic 
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events (CAPRIE) showed clopidogrel had modest overall benefit compared with 
aspirin in improving clinical outcome in patients with atherosclerotic native coronary, 
cerebrovascular or peripheral vascular disease^^ Nevertheless, its effect on improving 
early vein graft patency remains to be evaluated. 
Sulfinpyrazone and oral anticoagulants has shown inconsistent benefit with 
increased bleeding risk.^^ The CAB ADAS trial also showed that oral anticoagulation 
administered to attain prothrombin time ratio of 2.4 to 4.8 are equivalent, but not 
superior, to low-dose aspirin with or without dipyridamole in terms of 1-year vein 
graft patency rates.^^'^^ 
Moreover, of potential clinical relevance is the recently recognized occurrence of 
aspirin nonresponsiveness in a substantial proportion of patients undergoing CABG 
Whether this nonresponsiveness translates into increased early graft occlusion rates 
require further study. 
Thus, at the 6th American College of Chest Physicians consensus conference on 
antithrombotic therapy, a panel of experts drew a set of recommendations regarding 
antithrombotic use perioperatively from the evidence-based existing literature, which 
highlighted with the use of aspirin therapy, 325mg/d administered orally, starting 6 
hours after operation for 1 year for patients undergoing saphenous vein bypass 
grafting for coronary artery disease to reduce the frequency of saphenous vein bypass 
graft closure; and clopidogrel is recommended about 300mg as a loading dose 6 hours 
after operation followed by 50 to 100 mg daily for patients allergic to aspirin.^' 
Furthermore, the various vascular mediators released by the complex function of 
platelets at sites of vascular damage have been implicated adversely in accelerated 
intimal hyperplasia, therefore further researches have focused on the use of 
antiplatelet drugs to combat vein graft intimal thickening. For instance, it has recently 
been reported that topical aspirin delivery does reduce neointimal volume after vein 
grafting in mice; and clopidogrel has been shown to inhibit platelet adhesion and 
mitogenic signaling in vitro. This might be a new direction of antiplatelet therapy to 
be determined in the future. 
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Nitric oxide-donating aspirin 
As mentioned in antithrombotic therapy, aspirin is routinely administered to 
patients after CABG and continued indefinitely t h e r e a f t e r . T h e relative lack of 
effect on late graft failure has been ascribed to a lack of effects on vascular smooth 
muscle cell proliferation and minimal effects on the adhesion and release reactions of 
platelets and l e u k o c y t e s , w h e r e a s another major drawback of aspirin is the 
promotion of gastric erosion and ulceration over the long term.^^ Moreover, 5%-9% of 
patients are "aspirin resistant" and 23% are aspirin "semi-responders".^^ In contrast to 
aspirin, NO inhibits platelet and leukocyte adhesion and release of mitogens so as to 
inhibit neointima formation by inhibiting the proliferation and migration of VSMCs 
no 
and promote vasodilation with gastroprotection. 
One recent study of nitric oxide-donating aspirin (NCX 4016) showed that 
NCX4016 inhibited neointima formation and cell replication in porcine saphenous 
vein-carotid artery interposition grafts at dose as low as lOmg/kg.d for 1 month.^^ It 
elicits effects through both Aspirin- and NO- mediated mechanisms including 
inhibition of platelet function, inhibition of neutrophil adherence, reduction of blood 
pressure, and gastroprotection.^®"^^ In plasma, NCX 4016 releases NO in vivo for up to 
10 hours after administrat ion,�which is the principal moiety. Furthermore, NCX 
4016 also possesses antiatherogenic properties by inhibiting adhesion molecule 
expression in monocytes , inhibi t ing tissue factor expression, reducing superoxide 
formation, reducing nicotinamide adenine dinucleotide phosphate oxidase expression, 
cytokine release and caspase activity, all of which are mediated by the NO moiety of 
the drug.9o 
Endothelin-1 A antagonists 
Endothelin-1 (ET-1) is proved to be involved in every facet of vein graft 
disease，95-97 which can be summarized as follows: (1) ET-1 is released in large 
amounts by adherent blood cells such as platelets and leukocytes; (2) ET-1 promotes 
growth factor expression, matrix deposition and oxidative stress; (3) the saphenous 
vein contains high levels of ETa receptors that are expressed in the neointima 
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following graft implantation suggested it is vulnerable to pathologic attack by ET-1; 
(4) ET-1 synthesis is rapidly upregulated by all those factors associated with vein graft 
disease, including peptide growth factors, hypoxia and hemodynamic forces; and (5) 
early and later atherogenic events, including monocyte adhesion, are mediated by 
ET-1; (6) ET-1 also downregulates inducible nitric oxide synthase,^^ and nitric oxide 
on 
has been show to inhibit neointima formation. 
The effect of oral administration of the ETA antagonist BSF 302146 on vein graft 
thickening was studied in a porcine model of saphenous vein-carotid artery 
interposition grafting. It found a pronounced expression of ETA receptors in the 
neointima and the tunica media of saphenous vein grafts 1 months after implantation 
and demonstrated to promote a marked and dose-dependent inhibition of medial and 
intimal thickening, increased luminal area, and decreased PCNA-positive cells in 
porcine saphenous vein grafts mediated through inhibition of the proliferation and 
migration of VSMCs.^^ Other studies have also showed the inhibitory capacity of 
ET-1 receptor antagonists on neointima formation after balloon injury in other animal 
models and in an organ culture model of the human saphenous vein in vitro. 
In addition, there was marked positive remodeling in response to the 
administration of BSF 302146 in that luminal area increased in a dose-dependent 
manner. This is maybe due to the attenuation of matrix protein formation and 
deposition, in particular collagen and elastin, by ET-1 antagonist, which rendering the 
OO 
graft more susceptible to distension. 
Orally administered penicillamine 
In patients who have undergone CABG, blood copper levels are elevated for 6 
weeks after surgery, probably from the concomitant and sustained increase in plasma 
ceruloplasmin.iM In this context, vein grafts are associated with increased intragraft 
oxidative s t r e s s , w h i l e reactive oxygen species, however, including superoxide, 
peroxynitrite, and hydrogen peroxide, dissociate copper from its protein binding sites 
on ceruloplasmin and to fragment the p r o t e i n . I n turn, free endogenous intragraft 
copper may augment the vasculopathic effects and is established risk factor for 
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cardiovascular disease and atherogenesis and promotes oxidative stress, lipid 
oxidation, cell proliferation, matrix formation, and vascular inflammation, all 
components of neointimal formation and vein graft d i s e a s e . " � . � Thus, copper 
chelators are indicated to be evaluated for potential therapeutic effect. 
From a therapeutic perspective, penicillamine as a copper chelator is used to treat 
Wilson disease, systemic sclerosis, cysteine stones, and intractable rheumatoid 
arthritis. 112-113 Another copper chelator, thiomolybdate, has proven effective in 
reducing inflammation and has been purported to exert less serious side effects than 
other chelators. 114 in the porcine saphenous vein-carotid artery interposition grafts 
study by Wan et al, orally administered penicillamine has been demonstrated to be 
a potent inhibitor of neointimal formation, VSMCs proliferation and medial thickness 
with increasing luminal area as well. These data are consistent with previous studies 
of the oral administration of tetrathiomolybdate. ^ With concern to the marked 
enlargement of luminal area, the inhibitory effect on the deposition of matrix proteins 
by copper chelators might be the cause. 
Lipid-lowering drugs 
During the last two decades, indisputable proof of the beneficial effect of 
lipid-lowering therapy has been obtained and guidelines for its management have 
been extensively circulated. Treating hyperlipidemia, which has been identified as one 
of the most potent risk of graft atheroma, is now easy and safe using the 
3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) inhibitors (statins).^^ 
Meta-analyses of outcomes from 14 randomized angiographic trials indicated that 
treatment reduced the odds of disease progression in the native coronary arteries by 
490/0，and cardiovascular events by 47% after an average 30 mg/dl reduction of 
low-density lipoprotein cholesterol (LDL-C). '" 
However, there are a few angiographic trials have been specifically designed to 
evaluated the effect of lipid lowering in post-bypass patients in the past decade. The 
Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized 
placebo-controlled trial in 162 nonsmoking males who underwent previous CABG 
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surgery. It was the first trial with aggressive LDL-C lowering from a baseline mean 
level 171mg/dl to an average plasma concentration of 97mg/dl, and demonstrated 
significant reduction of new lesions as well as any adverse change in SV grafts in 
patients treated by combined colestipol and niacine therapy during a 2 years period. A 
substudy in 103 subjects treated for 4 years (CLAS-II) demonstrated a more 
significant reduction in the percentage of new lesions.''^ 
The lopid coronary angiography trial (LOCAT) randomized 395 post-bypass 
males whose high-density lipoprotein cholesterol (HDL-C) level ^ 42.5mg/dl, 
LDL-C level ^ 174mg/dl, and triglycerides level ^ 354mg/dl. The recruited 
patients were randomly assigned to l,200mg/day of gemfibrozil or placebo. In 14% of 
the 164 subjects assigned to placebo, SV grafts developed new lesions compared with 
only 2% of the gemfibrozil treated subjects (pcO.OOl)， 
The post-coronary artery bypass graft trial (post-CABG) included 102 females 
and 1,249 males who had undergone CABG with SV grafts 1 to 11 years before study 
entry, and randomly assigned to aggressive or moderate LDL-C lowering (using 
lovastatin and if needed cholestyramine) associated with warfarin or placebo therapy 
121 
using a 2 X 2 factorial design. After an average of 4.3 years, quantitative coronary 
angiography revealed that aggressive reduction of the LDL cholesterol level below 
lOOmg/dl, as compared with moderate lowering to a level near 130mg/dl, 
significantly reduced the progression of atherosclerosis in grafts by 30.8%. Although 
the occlusion rate was reduced by 45.5% and new lesions were less frequent by 52%, 
the 29% lower rate of revascularization was not significant due to the less designed 
power to detect differences in clinical events in this trial. Nevertheless, a 3-year 
extended follow-up study after 4.3-year post-CABG trial (7 years after 
randomization), showed a 30% reduction in revascularization procedures (p=0.0006) 
and a combined outcome including cardiac death, nonfatal myocardial infarction (MI), 
stroke, or need for revascularization was reduced by 24% Meanwhile, 
the finding of post-CABG study is consistent with the recommendation of the 
National Cholesterol Education Program that the LDL-C level should be reduced to 
below lOOmg/dl in patients who have coronary disease. 
2 0 
In addition, a substudy of the cholesterol and recurrent events (CARE) trial 
has also shown that pravastatin prevents clinical events in revascularized patients who 
have normal or slightly elevated cholesterol concentrations at baseline.i24 The 
predictor of survival, using the Cox proportional hazards model, selected the absence 
of a stenosis ^ 50% in any nonstented graft, and the use of lipid-lowering agents at 
follow up, emphasizing the importance of statin therapy in the post-CABG patients. 
Taken together, lipid lowering is strongly recommended in post-CABG patients 
with SV grafts. Unquestionable proof of the beneficial effect of lipid lowering in 
coronary artery disease and post-bypass patients has been demonstrated in numerous 
trials based on angiographic studies of the progression of atherosclerosis in native 
coronary arteries and SV grafts as well as on the occurrence of clinical events.^^ 
Therefore, properly managing hyperlipidemia in post-CABG patients is mandatory, 
although optimal LDL-C lowering target for secondary prevention remain to be 
clearly determined. 
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Summary 
Although some reports described the superiority of the free arterial conduits 
compared to the SV grafts, other studies also have suggested inferior patency rates for 
radial artery g r a f t s ^ ' a n d the LIMA plus SV grafts remains the standard composite 
of conduits for CABG Failure of coronary artery grafts may be multifactorial, 
especially due to the impact of the target-vessel characteristics, and it is noteworthy 
that the described patency of vein grafts always included poorer targets (such as the 
third and fourth position) than did the free arterial cohort, which need more data for 
further study.Nonetheless, in the modem era of careful conduit tissue handling and 
optimal use of antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, 
and p-blockers in the postoperative period, patency results with vein grafts can be 
achieved that are close of those achieved with free arterial grafts.'^ 
In short, because the durability of CABG is intrinsically dependent upon the 
patency of the graft, while the vein graft remains to be the essential conduit besides 
LIMA; the study to search for appropriate treatment regimes aimed at improving 
long-term vein graft patency must continue. 
With concern to the mechanism of aortocoronary saphenous vein graft failure, it is 
comprised of three distinct but interrelated pathological processes: thrombosis, 
neointimal hyperplasia, and atherosclerosis. The spectrum of risk factors predisposing 
to vein graft failure and its clinical sequelae is broadly similar to that recognized for 
native coronary disease, but pathogenic effects of these risk factors are amplified by 
loss of the anatomic and functional integrity of the endothelium during and after 
grafting, by transposition of the vein into the high-pressure arterial circulation. 
Important elements of preventive strategy will include: 1. avoidance of early 
thrombotic graft occlusion by continued improvements in surgical technique and by 
the optimal use of the most effective antithrombotic agents; 2. more intensive risk 
factor modification, in particular early and aggressive lipid-lowering drug therapy; 3. 
due to the improved understanding of pathogenesis, the continued exploration of new 
potential therapies, such as external stenting, and the administration of endothelin-1 a 
antagonists, NO donor, as well as the copper chelator and gene therapy, which target 
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the disease at an early and fundamental level (Figure 
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Chapter 2 
Animal Model and Laboratory Investigations 
A well-established porcine model of carotid artery-saphenous vein interposition 
grafting was used.(Figure 7) Female landrace pigs weighing 35-40kg, which received 
humane care according to the Home Office Animal Care Regulations, were randomly 
divided into several groups according to their required postoperative surviving 
durations (i.e., 1 week, 2 weeks, 1 month, and 3 months). Ethical approval had been 
obtained from Animal Experimentation Ethics Committee at the Chinese University 
of Hong Kong (Ref No. 06/039/ERG and CUHK4542/06M). Each pig underwent 
bilateral saphenous vein implantation into carotid artery system using end-to-end 
anastomoses under general anaesthesia. In the gene therapy study, all saphenous vein 
grafts were treated with adenoviruses-mediated gene (or a control gene) prior to the 
above-mentioned grafting procedure. At 1 week, 2 weeks, 1 month and 3 months after 
operation, the vein grafts were harvested. All the patent venous grafts received further 
immunohistochemistry investigation, western blot assay, and quantitative 
morphometric analyses on vascular remodeling. Subsequently, the animals were 




Figure 7. A porcine model of carotid artery-saphenous vein interposition grafting 
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Surgical procedure 
Induction of anesthesia was performed via atropine(0.5mg/10kg) + 
ketaniine( 1 Omg/kg) + xylazine(0.5mg/kg) cocktail administered intramuscularly, 
followed by 20% pentobarbitone diluted 5 times into 4% injecting intravenously (via 
ear vein using a 22G catheter), the amount was depended on the response of the pig, 
usually 4-6ml. Following intubation, anesthesia was maintained with 4% isoflurane in 
1:1 oxygen and nitrous oxide gas. Pigs were allowed to ventilate spontaneously and 
were provided normal saline intravenously throughout the operation, while 
monitoring the vital sign with ECG or pulse oxymeter. Amoxycillin 20mg/kg was 
administered intramuscularly before the operation proceeded to prevent postoperative 
infection. 
A longitudinal incision was made on the outer aspect of the hind limb. 
Approximately 10cm of the saphenous vein was then dissected free of surrounding 
tissue. Care was taken not to remove the adventitia. All side branches were secured 
with 3-0 silk (Ethicon Inc., Somerville, NJ, USA) ligature (Figure 8). The vein was 
removed from the animal, rinsed in iso-osmotic sodium chloride solution (0.9 g/L) 
containing 2IU/ml heparin and 50|ig/ml glyceryl trinitrate, and stored in the same 
solution at room temperature (23°C, 10-20 minutes) until needed. 
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Figure 8. Porcine saphenous vein harvesting: a. operation scene; b’c. dissecting saphenous vein with 
side branches ligatured. 
Two longitudinal neck incisions were made just medial to the stemomastoid 
muscles, and bilateral common carotid arteries were carefully dissected from the 
internal jugular veins and vagus nerves within the carotid sheaths. Heparin (Img/kg) 
was administrated intravenously after both common carotid arteries had been exposed. 
A 3-cm segment of the common carotid artery was isolated between vascular clamps 
and excised, beveling the cut ends obliquely to 45°C. The saphenous vein was cut to 
the appropriate length, reversed and similarly beveled, and an end-to-end anastomosis 
of the vein to the common carotid artery was carried out with a continuous 7-0 
polypropylene (Prolene; Ethicon Inc., Somerville, NJ, USA) suture. The wound was 
closed in layers after careful hemostasis. (Figure 9) 
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Figure 9. Porcine carotid artery-saphenous vein interposition grafting: a. dissecting common carotid 
artery; b,c. anastomosis; d. patent vein graft after anastomosis. 
At the end of the operation, the pig was ventilated with 100% oxygen for at 
least 20 minutes, injected with temgesic O.Olmg/kg intramuscularly and sprayed with 
nebacetin on wound surfaces. Animals were extubated and, when in a satisfactory 
condition, returned to their pens. 
Postoperative management 
Normal diet was resumed four hours after surgery. Over the first few 
postoperative days we took care of those animals in the Animal Laboratory at Prince 
of Wales Hospital till complete recovery. The pigs were then transferred to the 
Laboratory Animal Services Centre at The Chinese University of Hong Kong, where 
they were monitored and fed by the veterinarians until the date of graft-harvesting. 
After required postoperative period, each animal was reanesthetized as above, 
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with identified grafts through reopened neck wound. Each graft was removed, 
including l-cm segments of the proximal and distal carotid arteries. The harvested 
vein graft was first rinsed with normal saline and then divided into 2 segments with 
equal length. The proximal segment was snap frozen and stored in -70°C while the 
distal part was fixed in 10% buffered formalin. Subsequently, overdosed pentobarbital 
injection via the ear vein of the pig was used to sacrifice animals. 
Adenoviral-mediated gene transfer ex vivo for gene therapy study 
For study to evaluate the potential benefits of gene therapy in prevention of 
vein graft failure, we applied adenoviral-mediated gene transfer ex vivo during the 
surgical procedure associated with different post harvesting management: 
Under sterile conditions, the harvested saphenous vein was cannulated and 
flushed. The lumen of saphenous vein was washed through with sterile bathing 
medium (Dulbecco's modified Eagle's medium (DMEM) containing 20mM Hepes, 
2mM L-glutamine, 8ug/ml gentamicin, lOOIU/ml penicillin and lOOug/ml 
streptomycin). About 0.5ml recombinant adenovirus solution at 2.5*10^®pfu/ml was 
injected into the lumen without increased pressure and distension at room temperature. 
The distal end of the vein was clamped with an artery forceps and the whole specimen 
was immersed in bathing medium for 30 minutes. After half an hour incubation period, 
the vein was washed with 3ml bathing medium to remove any unused adenovirus 
left.2’3’6(Figure 10) 
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Figure 10. a，b. Adenoviral-mediated gene transfer ex vivo during surgery 
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After the required time period after operation, the harvested grafts were 
injected by using 10% buffered formalin with fixed pressure at 100 mmHg ex vivo for 
20 minutes, and post-fixed in the same solution for 24 hours before being rinsed and 
stored in phosphate-buffered saline at 4 � C . 
Laboratory investigation 
Immunohistochemistry 
Graft tissue was fixed in buffered formalin and paraffinized for 
immunostaining. Three antibodies included rabbit polyclonal anti-OPN (Abeam Inc., 
MA, USA), mouse monoclonal anti-PCNA (DAKO Inc., Denmark) and goat 
polyclonal anti-a-actin (Santa cruz Inc., CA, USA) were used. Briefly, 5|im section 
was deparaffmized and rehydrated, following antigen retrieval with 100°C citrate 
buffer and removal of endogenous peroxidase with 3% hydrogen peroxide. After that, 
the section was first incubated with appropriate dilutions of OPN(1:100) and 
PCNA( 1:400)，then incubated in corresponding horseradish peroxidase ( H R P ) -
conjugated secondary antibodies. An isotype-matched IgG was used instead of the 
primary antibody as negative control. The expression was visualized in brown color 
with the use of diaminobenzidine as a substrate, following counterstain of nuclei with 
haematoxylin. Images were examined under light microscope (Carl Ziess Inc., 
Germany) and captured by SPOT camera (Hitech Instruments, PA, USA). 
Western blotting 
Protein extract was obtained by homogenization of frozen graft tissue in 
radioimmunoprecipitation (RIPA) buffer. Protein concentration was determined by 
Bio-Rad protein assay. Under reducing condition, 25|Lig of protein from each sample 
was loaded into 10% sodium dodecyl sulfate polyacrylamide gel for the 
electrophoresis (SDS-PAGE). The separated proteins were then blotted onto Hybond 
nitrocellulose membrane (Amersham Biosciences, Germany). After that, the 
membrane was blocked for 1 hour with 5% non-fat milk in Tris-buffered saline 
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(pH7.4) with 0.1% Tween 20 and was then incubated with either rabbit polyclonal 
anti-OPN (1:1000; Abeam Inc., MA, USA) at 4 � C overnight. The blot was further 
incubated with HRP-conjugated secondary antibodies, following signal development 
using enhanced chemiluminescence detection. Band intensities were normalized with 
actin (1:1000; Santa cruz Inc., CA, USA) expression and were quantified using 
ImageJ software. 
Gelatin zymography 
MMP-2 and MMP-9 activity was determined by MMP zymography as 
described elsewhere. Briefly, 15|J,g of protein extract was loaded into 10% SDS-PAGE 
with 0.2% gelatin under non-reducing conditions. After that, the gel was washed with 
2.5% Triton-X 100 for 1 hour and was then incubated in developing buffer at 37°C 
overnight. Then, the gel was stained with 0.25% Coomassie blue R-250 for 30 
minutes, following destaining procedure with destaining solution (10% acetic acid 
and 50% methanol) until sharp clear bands appeared against blue background. The gel 
image was then scanned with an Epson Scanner 4990 (Epson Seiko Corporation, 
Japan) and analyzed with ImageJ software. 
Statistical analysis 
The numbers of grafts in each group are acceptable based on previously 
published studies of the same animal model. Values are presented as mean 士 standard 
derivation. All data were stored and analyzed using a standard computer statistical 
software program (Statistical Package for the Social Sciences 12.0; SPSS Inc，Chicago, 
111). Mann-Whitney U and Kruskal-Wallis tests were used to determine the inter-group 
differences followed by Spearman's rank correlation coefficient used for correlation. 
Statistical significance was inferred at two-sidedp values less than 0.05. 
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Summary 
This porcine model of carotid artery-saphenous vein interposition grafting 
offers a convenient and clinical-relevant model which is highly reproducible. It also 
provides an opportunity to study the efficacy of gene therapy in a preclinical setting 
for CABG and may produce new insights into the planning of future clinical trials. It 
has been clearly demonstrated that ex vivo gene transfer through a 
replication-deficient, recombinant adenovirus vector using a delivery technique 
unlikely to damage the vessel endothelium is achievable in saphenous vein grafts. 
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Chapter 3 
Impact of Osteopontin Expression in Vein Grafts on VSMC 
Migration, Proliferation, and Neointimal Formation 
Introduction 
Osteopontin (OPN) is a multifunctional phosphorylated acidic glycoprotein 
identified in 1979/ which was originally isolated from the bone. It possesses the 
tripeptide arginine-glycine-aspartic acid sequence (Arg-Gly-Asp; RGD) existing both 
as an immobilized extracellular matrix (ECM) component protein and a soluble 
molecule implicated in inflammation, cell-mediated immunity^ tissue remodeling and 
tumor metastases?'^ A wide range of cell types including some epithelia, macrophages, 
T cells, and vascular smooth muscle cells (VSMCs) express OPN in a constitutive or 
inducible fashion.^'^ OPN functions as a cell adhesion and migration molecule that 
can bind to several ligands including cXvp3 integrin, CD44, and fibronectin,^ while 
emerging as a key factor in both vascular remodeling and in the development of 
atherosclerosis recently, since Giachelli et al. first showed its potential function in 
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neointima formation in 1993.“ 
OPN gene expression is absent from the endothelium of normal arteries,^'but 
is strongly up-regulated in areas of endothelial damage.^'^'''^ It has been reported to be 
a major constituent of atherosclerotic plaques,^'^^ as well as a distinctive feature to 
promote VSMC migration and proliferation in arterial injury animal modeling, such 
as rat and bovine aortic model.^'''^ Whereas, it also has been demonstrated that high 
levels of OPN mRNA and protein are detectable in the rat and human aorta and 
carotid arteries during neointima formation.^'^''^ 
Integrins, a family of heterodimeric glycoprotein subunits designated a and [3, 
play a pivotal role in mediating cell adhesion during m i g r a t i o n / w h i l e OPN binds 
different integrins and CD44 splicing isoforms. Various experimental evidence 
implicates avp3 integrin as the OPN receptors responsible for the observed effects of 
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OPN upregulation on cell movement.'^ Conversely, it has been demonstrated that 
OPN or its integrin receptors blockade by neutralizing antibodies, RGD antagonist 
peptides, and OPN deficiency in OPN null mice significantly prevent neointimal 
thickening and attenuate atherosclerosis，�’'9 which could be a promising therapeutic 
strategy to limit the development of restenotic lesions or atheromatous plaques. 
However, most published data came from in vitro trials and arterial models. The 
present study was designed to evaluate the in vivo expression of OPN in the vein 
grafts in a pig model of saphenous vein-carotid artery interposition grafting, and to 
explore its potential impact on the development of neointimal hyperplasia. 
Materials and methods 
In total, 16 pigs were included in the current study. In the 3-month group, one 
pig died of pneumonia 2 months after surgery, and two other grafts were found to be 
occluded. Eventually 28 patent grafts were removed at 1，2, 4，and 12 postoperative 
weeks, respectively. In addition, 8 sections of saphenous veins taken immediately 
after harvesting (prior to interposition grafting) were used as the controls. Hence, 
there were 8 grafts in each group except only 4 grafts in the 3-month group. 
The detailed description of the study protocol could be referred to Chapter 2. 
Results 
OPN protein expression in vein graft 
We first sought to determine the OPN expression at different time points 
postoperatively by immunostaining and western blot assay. The results indicated that 
OPN protein expression increased a large amount to peak at first week postoperatively 
(p二0.021，Mann-Whitney test) when it appeared more in the intima of the vein graft; 
whereas its expression declined at 2nd postoperative week when the majority of 
expression was in the media. From 2nd week to 3 months the expression declined 
gradually but still had significant increase compared with control (p=0.021，0.021 and 
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0.043 for 2 weeks, 1 month and 3 months, respectively, Mann-Whitney test). 
(Figure 11-13) 
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Figure 11. Representative western blots showing osteopontin (OPN) level in vein grafts 
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Figure 12. Change in OPN expression of porcine saphenous vein after grafting. Results are shown in 
mean+/-sd. * p<0.05 when compared to control group. 
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Figure 13. Representative immunostaining of osteopontin (OPN: in red color) on vein grafts at 
different time points after carotid artery-saphenous vein interposition grafting surgery: a. before 
operation; b. 1 week; c. 2weeks; d. 1 month; e. three months. The scale bar represents 100 |im and is 
applicable to all images. 
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Matrix Metalloproteinases (MMPs) activities and its correlation with OPN 
expression 
We performed gelatin zymography to confirm whether MMP-2 and MMP-9 was 
expressed in the vein graft and its trend at different time points post surgery. The 
amount of pro MMP-2 and active MMP-2 as well as pro MMP-9 increased to the 
peak at 1 st week with gradually decrease from 2nd week to 3rd months after surgery. 
Compared to control, both MMP-2 expression at all time points were significantly 
higher (p二0.003 and 0.012 when compared among different time points, 
Kruskal-Wallis test; p=0.021 when compared different time points with control, 
Mann-Whitney test), while both MMP-2 expression also positively correlated with 
OPN protein expression (r二0.623 and 0.531，p=0.003 and 0.016, respectively, 
Spearman's rank correlation). Meanwhile, there was statistical significance when 
compared pro MMP-9 at most time points with control except one time point 
(p=0.012, Kruskal-Wallis test; p=0.021 for 1 week and 2 weeks time points, p=0.043 
for 1 month time point, and p=0.773 for 3 months time point, Mann-Whitney test), 
which also associated with significant correlation coefficient with OPN expression 
(r=0.468, p=0.038 Spearman's rank correlation). These findings indicated that OPN 
might stimulate MMP-2 but not MMP-9 production in this vein grafting model. 
(Figure 14-15) 
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Figure 14. Representative gelatin zymogram for MMP-2 and MMP-9 at different time points after 
surgery 
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OPN and MMPs Expression at Different Time Points 
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Figure 15. OPN protein expressions with pro MMP-9, pro MMP-2 and active MMP-2 at different time 
points 
VSMC Proliferation 
Because OPN is known to promote VSMC proliferation in W/ra6’i4’2o，2i ^nd in 
mice overexpressing OPN," we determined whether there was a media VSMC 
proliferation in our vein grafting model by immunostaining of proliferating cell 
nuclear antigen (PCNA) on vein grafts at different postoperative time points. The 
nuclei of proliferated VSMCs stained positively for PCNA. 
By 1 week after surgery, the media of vein graft showed a significant increase 
in PCNA-positive VSMC nuclei (Figure 16, b), in contrast with the only rare positive 
staining VSMC nucleus in the control group (Figure 16, a). Although the 
PCNA-positive VSMC nuclei peaked at 1 week postoperatively, it gradually 
decreased with subsequently reducing to level of control group at 3 months after 
surgery (p二0.002, Kruskal-Wallis test) (Figure 16，c-e). Nonetheless, the percentage 
of PCNA positive VSMCs' also got significant correlation coefficient with OPN 
protein expression at different postoperative time points (r=0.605, p=0.005, 
Spearman's rank correlation, Figure 17). 
This result indicated that vein graft-induced VSMC proliferation might be a 
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multifactorial process which influenced by a wide range of contributing factors (eg. 
bFGF, ET-1, PDGF), and OPN is one of the contributing factors to promote the 
process. 
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Figure 16. Representative immunostaining of proliferating cell nuclear antigen (PCNA: in brown color) 
on vein grafts at different time points after grafting: a. before operation; b. Iweek; c. 2weeks; d. 
1 month and e. three months. The scale bar represents 100 |im and is applicable to all images. 
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OPN Expression Correlated with PCNA Counting 
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Figure 17. OPN expression correlated with PCNA counting (percentages of PCNA-positive stained 
VSMCs • 100) at different time points 
Discussion 
To our knowledge, this is the first in vivo study on the induction of OPN in 
vein grafts. Our data showed that the early induction of OPN in vein grafts correlated 
with an upregulated MMPs activity and VSMC proliferation, which may 
consequently contribute to neointimal hyperplasia and the development of late vein 
graft failure. 
Early thrombosis and intimal hyperplasia with consequent atherosclerosis are 
long thought to be the primary causes and major pathological process of graft 
failure.22-25 Within the first month after bypass grafting surgery, the principal 
underlying mechanism is graft thrombosis, caused by arterialization of the vein grafts 
attributing to the combined effects of altered flow dynamics, alterations in the vessel 
wall and changes in blood rheology.^ '^^ "^ However, neointimal hyperplasia is the major 
disease process in venous grafts before 1 year after vein graft implantation, defined as 
a process that involves continued migration and proliferation of VSMC into the intima 
compartment, often associated with deposition of extracellular m a t r i x . I t has been 
strongly suggested that neointima hyperplasia attributes to extensive endothelial 
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denudation and destruction related with vigorous luminal distension during surgery, 
damage at surgical anastamoses, and continued physical trauma under arterial 
conditions. As such, initially, medial VSMCs proliferate in response to a number of 
growth factors, adhesion molecules and cytokines released from platelets and from 
activated endothelial cells and macrophages (i.e. PDGF, VCAM, ICAM, Cdks, OPN 
and E2F, etc).^^ This is followed by migration of VSMCs into the intima, with 
subsequent further proliferation. It is also worth noting that the synthesis and 
deposition of extracellular matrix by activated VSMCs leads to a progressive increase 
in intimal fibrosis and a reduction in cellularity?^ There is now accumulating evidence 
that MMPs, the physiological mediators of matrix deposition and degradation, play an 
important role in the development of neointima formation following arterial bypass. 
Subsequently, neointimal hyperplasia represents the foundation for later development 
of graft atheroma, possibly through accelerated lipid accumulation and monocyte 
transmigration. The extensive intimal hyperplasia throughout the length of a vein graft 
as a nidus may effectively create a diffuse atherosclerosis-prone region, whereas 
atherosclerosis becomes predominant process underlying the attrition of saphenous 
vein grafts and the eventual recurrence of ischemic symptoms beyond the first year 
after bypass surgery. The present study has explored the underlying marker (OPN) 
and mechanism of the neointima formation process in a porcine vein graft model. 
Recently, OPN, a bone-associated protein, has been implicated in vascular 
remodeling. One study on OPN-transgenic mice by Isoda et al}^ demonstrated that 
OPN overexpression was associated with a significant increase in medial thickening 
with aging in vivo and in intimal thickening after arterial injury. With concern to the 
mechanism of OPN overexpression contributing to vascular remodeling, one in vitro 
study by Leali et al}^ suggested that OPN upregulation impairs reendothelialization 
by inhibiting the first phase of the cell migration cycle via avP3 integrin engagement 
by the extracellular matrix-immobilized protein. Another in vitro experiment with 
cultured coronary artery VSMCs by Panda et al.沙 indicated that OPN plays both 
autocrine and paracrine receptor-mediated roles, which critically affect the biology of 
coronary artery VSMCs. This also mentioned by L e a l i L i a w ' * and Xuan^^ that 
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soluble OPN exerts a chemotactic effect on endothelial and VSMCs following 
integrin engagement. Moreover, Jalvy et al showed that PDGF stimulation of 
VSMCs leads to the expression of OPN, and extracellular OPN autocrinally produced 
by VSMCs plays a major role in the activation of the migration process induced by 
the reference VSMC chemotactic factor PDGF. These results may contribute to the 
adverse effects exerted by OPN in restenosis and atherosclerosis, while they suggest 
the important role of OPN in the pathological processes associated with VSMC 
migration and proliferation. Our data demonstrated that OPN overexpression after 
vein grafting, with peaking at nearly 9-fold amount compared with control, whereas 
after 2nd week, OPN obviously appeared in the media. This result positively 
correlated with the PCNA-positive VSMC nuclei amount in the vein grafts at different 
time points. 
The matrix metalloproteinase family is an important group of proteolytic 
enzymes that can digest all the components of the extracellular matrix and are closely 
involved in the vascular remodeling, migration, and proliferation of VSMCs.^^ 
MMP-2, also known as the 72-kDa IV collagenase and gelatinase A, is an important 
member of the MMP family and is closely associated with the cardiovascular system. 
It can be activated to form the 62-kDa active MMP-2 by degrading 80 amino acids 
from plasminogen secreted by VSMCs. Exhibiting many degradation activities, 
MMP-2 is the main enzyme that degrades extracellular matrix and basement proteins, 
such as collagen and elastin, and enhances VSMC migration. Collagen is the most 
abundant component of extracellular matrix proteins which surrounded VSMCs and 
endothelial cells in the vessel wall and comprising more than 50% of the total protein 
in the restenosed vessel wall. It forms a migration barrier for VSMCs, which serves as 
the main component of neointimal hyperplas ia . The analysis by Isoda and 
colleagues also confirmed that MMP-2 or MMP-9 did increase in the aorta of 
OPN-transgenic mice, while they were not expressed to a significant degree in the 
normal mouse aorta." More studies suggest that MMP-2 and MMP-9 are involved in 
vascular remodeling associated with vascular disease and injury, resulting in arterial 
obstructive disease.�！ Steipelt and colleagues�] studied vascular healing of rabbit 
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thoracic aortas, which briefly exposed to OPN, and detected rapidly upregulated 
MMP-2 activity 2-fold compared with control aortas with return to time 0 level by 1 
month, subsequently confirmed the involvement of MMP-2 in vascular remodeling 
after injury. Our study indicated nearly 15-fold upregulation of both pro MMP-9 and 
pro MMP-2 as well as almost 20-fold rise of active MMP-2 expression at 1 week after 
vein grafting in a porcine saphenous vein-carotid artery interposition grafting model. 
The increase in the amount of MMP-2 may thus play an important role in the 
destruction of the elastic lamina and the promotion of the explant migration of 
VSMCs. This was also consistent with the temporary increase in VSMC proliferation 
within the intima and media, which both might attribute to OPN overexpression in the 
vein graft after interposition grafting surgery. 
On the other side, previous studies have demonstrated blockade or inhibitors 
of avp3 integrin, which is the OPN receptor and mediator of VSMC migration after 
vascular injury, resulted in a reduction of neointimal formation.^^'^^ Panda and 
colleagues showed that transfection of VSMCs with lipofectin containing 
OPN-antisense S-oligonucleotides causes a drastic inhibition of proliferation of these 
cells, that may have potential clinical application as one strategy to prevent 
reocdusion.20 Another study reported by Liaw et al. indicated that neutralizing 
antibodies against OPN decreased the neointimal areas and cell numbers after 
endothelial denudation.� 
Summary 
This study demonstrated that OPN potentially associated with MMP-2 plays 
an important role in the development of VSMC migration, proliferation and intimal 
hyperplasia in vein graft. While inhibitors of OPN or its receptor might be useful 
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Chapter 4 
Potential Role of Gene Therapy in Prevention of Vein Graft Failure 
Much interest in reducing neointimal hyperplasia by blocking gene expression 
is arising given the better understanding of the cell cycle of endothelial and smooth 
muscle cells. Understanding this background has allowed applied genetics to tackle 
aspects of vein graft failure such as thrombosis, neointimal hyperplasia and 
accelerated atherosclerosis. Genes that could influence these processes will ultimately 
influence vein graft patency and in turn determine the long-term morbidity and 
outcome.‘ 
There are reiterations of some principles about gene therapy, for instance, the 
composition of a transgene, the various methods of how a transgene can be inserted 
into a cell, and the mechanism by which a cell expresses the transgene.^"^ However, 
successful application of gene therapy to prevention of venous bypass graft failure 
requires the selection and the testing of suitable gene-delivery vectors, applicable 
cellular promoter systems to drive transgene expression and efficient therapeutic 
transgenes that together mediate phenotypic gain in the required time frame for 
success at prevention of late graft failure. 
Vectors 
Insertion of recombinant genes can be classified as chemical facilitators, 
electroporation，direct microinjection, liposomal delivery, and viral vectors/ 
Nevertheless, chemical facilitators can only be used in tissue culture secondary to 
technical considerations, while efficacious currents of electroporation often approach 
500 V and are associated with cell mortality approaching 50% in suspension cultures, 
and microinjection involves the direct injection of recombinant genes into the 
cytoplasm or nucleus under high-power magnification.^ Therefore, these methods of 
gene transfer will not reach clinical applicability in the treatment of cardiovascular 
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disease secondary to the inherent graft injury associated with their application. 
The current methods of gene transfer which have clinical potential are 
liposomal delivery and viral vectors. Liposomal gene therapy utilizes lipids as carriers 
for the recombinant gene until incorporation into the cell. Internalization of the gene 
into the cell as an endosome is favored by the positive lipid charge in a process called 
endocytosis.7 
On the other side, three main classes of viral vectors have been utilized: 
adenoviruses (Ad), adeno-associated viruses (AAV), or retroviruses.''^'^ AAV is a 
small, nonautonomous virus composed of linear single-stranded deoxyribonucleic 
acid (DNA) and the constraint in generation of this vector is the length of the 
recombinant gene, which must be less than 4,680 base pairs according to the length of 
the viral genome. Retroviruses are a large class of enveloped viruses that consist of 
single-stranded ribonucleic acid (RNA) as the viral genome and, consequently, require 
a reverse transcriptase to generate DNA copies of the RNA genome after viral 
infection of cell. It is capable of integrating within the human chromosome in dividing 
cells, thereby imparting long-term expression of the recombinant gene; whereas the 
major limitation is random insertion causing mutations and the difficulty establishing 
their safety and efficacy.8 To date, Ad vectors, a double-stranded, linear DNA virus, 
can be singled out as the most suitable system for vascular disease given its ease of 
high titer generation, easy handling, large insert capacity and extensive 
characterization? It is becoming more favored as a gene therapy vector because of its 
ability to infect a large number of both dividing and non-dividing cell t y p e s . � 
Reporter gene, timing and the titer 
Gene therapy is dependent not only on the vector utilized but also the gene 
insert, and the subsequent expression of the gene differs importantly between 
vasculature beds. Tsutsui et al. found that p-galactosidase (p-gal), essentially a 
nonfunctioning but easily identified gene, was expressed differently following 
adenoviral transfer in canine basilar, coronary, and femoral arteries;" similarly, 
57 
various animal models of vein graft disease have also been studied in reporter gene 
trials with positive r e s u l t s . M o r e o v e r , several studies have been performed to see 
if human saphenous vein (SV) graft can express reporter genes such as (3-gal 
following various transfer methods, including use of an adenoviral vec tor” 
Theoretically, SV grafts are ideal targets for gene therapy because the 
explanted veins are available for ex vivo transfer of genetic material before grafting. 
The transfer rates in veins were decreased when performed 3 days after implantation 
compared to transfer at the time of graft construction.'^ 
Another factor that may impact on subsequent gene expression is the promoter 
utilized. Most of the experiments in vein grafts have used either the cytomegalovirus 
immediate early promoter (CMV-IEP) or Rous sarcoma virus long terminal repeat 
(RSV-LTR) promoters.^ In addition; the titer, or amount of virus used for the gene 
transfer has also been found to influence subsequent gene expression with a 
dose-dependent manner/ 
Candidate genes 
Antisense gene transfer 
One strategy is to insert a gene which prevents the natural production of a cell 
product. Rather than augmenting the production of a cell product (i.e., nitric oxide), or 
producing something which the SV graft does not naturally produce (i.e.，hirudin), 
antisense technology inhibits the production of a normally produced product. 
Golden and colleagues have used adenoviral-mediated transfer of a gene 
antisense to basic fibroblast growth factor (bFGF), which stimulates VSMC 
proliferation, to inhibit vein graft neointimal hyperplasia, and demonstrated greater 
mean vein graft wall thickness with unchanged cross-sectional area leading to 
significantly decreased tangential wall stress.'^ Mann et al. used liposomes to deliver 
a single dose of cyclin-dependent kinase 2 (cdk2，which coordinates numerous events 
in the cell cycle with controlling DNA replication and transcription) antisense 
oligonucleotides to rabbit jugular vein grafts, and demonstrated preserved endothelial 
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function of rabbit vein grafts.'^ In like manner, significant reduction in neointimal 
hyperplasia was noted by Morishita and colleagues who used similar technology in 
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injuried rat carotid arteries. 
Transcription factor E2F, responsible for the upregulation of a dozen cell-cycle 
genes that mediate mitosis, is a potential target for the inhibition of neointimal 
hyperplasia. Mann and colleagues have used an antisense oligonucleotide (edifoligide) 
to block this transcription factor in a series s t u d i e s . I n a clinical trial performed in 
41 patients undergoing peripheral bypass surgery, grafts treated with E2F decoy had 
decreased expression of mRNA and decreased DNA synthesis from E2F transcription 
factor-mediated genes (c-myc and proliferating cell nuclear antigen). Subsequently, 
the edifoligide treated group had reduced rates of high-grade obstructions on 
ultrasonography at a median follow-up of 53 weeks (PREVENT l)?^ In PREVENT II, 
200 patients undergoing CABG at a single center in Germany were randomly 
assigned to ex vivo vein grafts treatment with edifoligide or placebo. Intravascular 
ultrasound studies were evaluable in 65 patients and showed a decrease in mean graft 
wall volume as well as mean vessel wall volume index which suggest a favorable 
effect on graft remodeling.^' In addition, E2F decoy therapy has been further defined 
in animal models, such as rabbit jugular vein grafts, and demonstrated a significant 
reduction in neointimal hyperplasia as well as attenuated VSMC proliferation at 6 
22 
weeks and 6 months. 
The recently published PREVENT IV trial is a multi-center, randomized, 
double-blind, and placebo-controlled trial of 3014 patients undergoing CABG surgery 
with at least 2 planned saphenous vein grafts and without concomitant valve surgery, 
who have enrolled between August 2002 and October 2003 at 107 US sites.^^ Vein 
grafts were treated ex vivo with either placebo or edifoligide, an E2F decoy, in a 
pressure-mediated delivery system. The results published on JAMA 16 Nov. 2005 
indicated that no difference in vein graft patency at one-year was found; no difference 
in cardiac events was noted; in addition, the mean graft diameter (an angiographic 
marker of neointimal hyperplasia) measured by quantitative angiography was not 
different between E2F decoy and placebo SV grafts. Nonetheless, longer-term 
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follow-up (3-5 years) and additional research are needed to determine whether 
edifoligide has delayed beneficial effects，to understand the mechanisms and find the 
novel markers and therapeutic strategies of vein graft failure, and to improve the 
durability of CABG surgery. 
Tissue inhibitors of metalloproteinases (TIMPs) 
For the development of neointimal hyperplasia, VSMC proliferation and 
migration are key events forming the most prominent cellular element of the 
neointimal lesion that require the degradation of matrix proteins and the elastic 
laminae.24 Matrix metalloproteinases (MMPs) are zinc-dependent enzymes that 
mediate matrix degradation and deposition, while the physiologic antagonists of the 
MMPs are serine proteases and specific tissue inhibitors of metalloproteinases 
(TIMPs). Four isoforms of endogenous TIMPs have been identified, three of which 
have been cloned. Thus, overexpression of TIMPs to block the action of MMPs has 
been extensively analysed ex vivo in human saphenous vein organ cultures and in 
porcine grafts in vivoP'^^ A series of experiments transferring TIMP-1, TIMP-2, or 
TIMP-3 to human SV graft has been described by George and colleagues, and showed 
that neointimal hyperplasia was significantly reduced 79%-84% with TIMPl-3 
transfer. However, TIMP-3 was indicated to be effective at blocking neointima 
formation in porcine carotid-vein interposition grafts in vivo. ‘ This was attributed 
to the ability of TIMP-3 (but not TIMP-1 or -2) to bind the extracellular matrix and/or 
its ability to promote SMC apoptosis in addition to blocking migration.^^'^^ 
The effect on neointima formation was effective at 28 days post grafting. 
Longer time points may be important, as arterial gene delivery of TIMPs can block 
early effects on neointima hyperplasia in angioplasty models, but a "catch-up" effect 
dampens the effect at later time points?^'^® 
Proapoptotic gene p53 
The tumor suppressor p53 is mediated by human senescent cell-derived 
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inhibitor gene-1 (sdi-1). Bai et al. demonstrated a 70% inhibition of neointimal 
formation using this strategy of gene therapy in rabbit vein grafts two weeks after 
surgery.^' Also it is worth noting that the phenotypic modulation of the predominant 
VSMC type, favoring adult type versus embryonic, was found following sdi-1 gene 
transfer.31-32 
George and colleagues have previously shown that promotion of apoptosis 
with reduced VSMC migration by overexpression of p53 in human SV grafts ex vivo 
may be a useful strategy for the prevention of vein graft neointimal hyperplasia in 
vivo?^ Our team has demonstrated overexpression of p53 increased lumen size and 
blocked neointima formation in porcine interposition vein grafts.^^ 
We transferred the proapoptotic gene p53 at the luminal surface of SV grafts 
using adenoviral-mediated technique in our porcine model prior to grafting and 
compared with adenoviral-mediated p-gal infected (Adp-gal-infected) grafts at 7 and 
28 days. The overexpression of p53 induced a significant upregulation in apoptosis 
and a remarkable reduction of neointimal proliferation by 28±1% at day 7 post 
infection. Adp5 3-infected grafts had significantly greater luminal areas with reduced 
thickening of the neointima at both time points. In addition, total grafts areas were 
increased at 28 days following p53 overexpression, indicating positive vessel 
remodeling when comparing to the previous TIMP-3 study which showed no effect on 
lumen or vein graft area.^ '^^ ^ Importantly, phenotypic changes were maintained at 3 
months which demonstrated a sustained effects of p53 treatment.^^ It implies that the 
use of vectors that provide long-term transgene overexpression may not be required. 
Although late vein graft failure has a progressive pathobiology, transient 
overexpression of therapeutic genes may suffice since many of the remodeling events 
associated with vein grafts occur acutely within the first days and weeks.^ "^ "^ ^ 
Potential therapeutic effects of Nogo-B 
Ad-Nogo-B (Ad-Ng-B) inhibits proliferation and migration of VSMCs in vitro 
As VSMC migration and proliferation are key steps in the vascular remodeling, 
Kirtz et al has observed a significant reduction in the number of viable cells as early 
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as 48 hours after infection with Ad-Ng-B as compared to infection with Ad-p-Gal in 
proliferation murine VSMCs as well as in porcine VSMCs, while did not see any 
effect on cell death or cell survival; which indicated that Nogo-B is a potent inhibitor 
of VSMC proliferation but does not regulate cell apoptosis.^^ 
Secondly, they also presented that overexpression of Nogo-B reduced VSMC 
migration both with and without stimulus in cells derived from wild-type (WT) and 
Nogo-knockout [Ng-A/B (-/-)] mice, as well as PDGF-induced migration in porcine 
VSMCS.36 
Ad-Ng-B prevents neointimal hyperplasia caused by vein grafting in pigs 
In our cooperative study, we looked at the effect of Ad-Ng-B gene delivery to 
saphenous vein interposition grafts in the porcine model, to determine whether the 
protective effect of Nogo-B is broadly applicable to diverse strategies to prevent 
neointimal hyperplasia. As described in Chapter 2 previously, pig saphenous veins 
were explanted, infused intraluminally with 2.5 * pfu of either Ad-Ng-B or 
Ad-p-Gal for 30 minutes prior to grafting, and the pigs were allowed to recover 
finally. The grafts were removed at 28 days after operation to compare the effects of 
Nogo-B treatment on vascular remodeling by quantitative morphometry of 
hemotoxylin-staining, and revealed that: the neointimal area of Ad-Ng-B-treated 
grafts was significantly reduced as compared to Ad-p-Gal-treated grafts (2.87min^ 
versus 7.44 mm^; p=0.0007). The total vessel area (18.09inm^ versus 29.54mm^; 
p=0.034) and the intima:media ratio (0.32 versus 0.55; p=0.0044) were also 
significantly reduced, whereas there were no significant differences in luminal or 
medial areas.(Figure 18) Collectively, these data showed that overexpression of 
Nogo-B prevented neointimal hyperplasia but did not affect VSMC apoptosis in the 
porcine vein graft model in vivo?^ 
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Figure 18. Ad-Ng-B prevents neointima formation caused by vein grafting in pigs. a. Rescue of 
injury-induced loss of endogenous Nogo-B with Ad-Ng-B in vein grafts 7 days after grafting, b. 
Hematoxylin-staining and c. quantitative morphometry measurements of Ad-^-Gal and 
Ad-Ng-B-transduced vein grafts 4 weeks after grafting.. Neointima (NI), media (M), and adventitia (A). 
Bai^ SOO^ im. *p<0.05, **p<0.01 versus Ad-P-Gal.^ ^ 
Other strategies of gene therapies 
In broad terms (apart from early thrombosis), modulation of VSMC migration, 
proliferation and/or apoptosis, acceleration of endothelial re-endothelization and 
improvement in endothelial function are the most pertinent systems to modulate in 
order to improve graft patency.^'^ 
The endothelium produces three factors which causes vasodilatation, 
collectively known as endothelium-dependent relaxing factors: prostacyclin, nitric 
oxide, and endothelium-derived hyperpolarizing factor (EDHF). Although therapeutic 
gene transfer study of prostacyclin has just been specifically reported in arterial 
models and EDHF remains to be defined chemically, gene vectors for nitric oxide 
synthase (NOS) have been examined to introduce the NOS gene into the endothelium 
of the saphenous vein in order to prevent neointimal hyperplasia. Cable and 
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colleagues demonstrated a tenfold increase in stimulated nitrite production with 
significant reduction of intimal hyperplasia in human SV graft following 14 days of 
organ culture after transfer of endothelial nitric oxide synthase (eNOS).'^ Similarly, 
Matsumoto et al. utilized a liposomal transfer of bovine eNOS in a canine vein graft 
model of poor-runoff, showing significantly reduced intimal thickness (90|J,m) 
compared to both vehicle and vector (193|im) controls after 4 weeks.^^ 
Although, there had been no studies that directly addressed the use of gene 
therapy for prevention of thrombosis in coronary grafts, extrapolation of results from 
angioplasty mediated injury to the animal arterial and venous models has been 
encouraging, such as gene transfer of hirudin, thrombodulin and tissue plasminogen 
activator (tPA), associated with decreased intravascular thrombosis and reduced 
t h r o m b o g e n i c i t y . 3 8 " ^ 2 jj^  addition, retroviral gene transfer of tPA to venous endothelial 
cells has been subsequently seeded onto synthetic grafts, raising another interesting 
prospect of selective anticoagulation of vein grafts via gene therapeutics."^^ 
Summary 
Transgene delivery to SV grafts is valuable because multiple molecular 
pathways have been identified as important contributors to neointimal hyperplasia and 
may represent targets for treatment. Inhibition of intracellular superoxides, 
extracellular matrix metalloproteinases, and nuclear apoptotic proteins impede VSMC 
proliferation and vascular neointimal formation.'^^"^^ We also found gene-delivery of 
Nogo-B exerts a positive effect on vein graft remodeling by reducing neointimal 
hyperplasia in our porcine vein graft model. 
Gene therapy has enormous potential to apply localized therapy to each 
individual vein graft while keeping the circulatory system undisturbed. In addition to 
affecting thrombosis and hyperplastic response within the vein grafts, gene therapy 
may also provide an opportunity to modulate vascular function in the grafted territory, 
providing a "downstream effect”？ which might prevent subsequent atheroma 
development as well. 
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Despite the theoretical advantage, there has been little real success following 
the first clinical trial in gene therapy with adenosine deaminase-deficient patients in 
1990. To date, the only reported data from a clinical trial on vein graft disease 
following CABG showed that gene transfer of a decoy oligonucleotide was not more 
effective than placebo. The methods of gene transfer, inflammatory response to 
either the vector or the transgene proper, safety of gene transfer in the specific 
anatomical targets, proper duration for gene expression, feasibility for repeating gene 
delivery, and viable clinical endpoints all need to be fully addressed in the future.^ 
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CABG using saphenous vein conduits, in addition to the arterial grafts, 
remains the standard for treatment of intractable angina due to coronary artery 
occlusive disease. Over the past four decades, this procedure has stood the test of time 
with excellent results as measured by a variety of outcome markers. However it was 
also evident that CABG provides only palliation to an ongoing process that is further 
complicated by the rapid development of vein graft failure. 
According to the current understanding of the mechanism involved in vein 
graft failure following CABG, this pathological process may evolve over three phases. 
In the early phase, namely the first month after surgery, thrombosis is a major cause of 
vein graft attrition. Between 1 and 18 months after CABG, neointimal hyperplasia in 
the venous wall is the fundamental change that forms a template for the subsequent 
atherogenesis phase and eventually leads to late vein graft failure. Each process 
occurs along a spectrum of time frames triggered by endothelial injury and 
perpetuated by a cascade of inflammatory reactions from the vascular matrix and 
leucocytes acting primarily on endothelial cells and VSMC. It is likely that VSMC 
migration and proliferation, following simultaneous MMPs activities, interferes with 
the relative proteolytic balance. Targeting at different processes of the progressive 
vein graft restenosis, the emerging therapeutic strategies include various 
pharmacologic therapies on top of antiplatelet and lipid-lowering drugs, external 
stents，and gene therapy. Nonetheless, protecting the vessel endothelium by 
minimizing distension pressures remains essential in limiting neointimal hyperplasia 
of the vein graft. 
Using our well established porcine model of carotid artery — saphenous vein 
interposition grafting and applying an appropriate delivery technique with an 
adenoviral vector, we have demonstrated that ex vivo gene transfer was feasible in the 
vein grafts. Moreover, we noted that Nogo-B overexpression resulted in significantly 
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reduced neointima formation by limiting VSMC proliferation and migration. In 
addition, we found that the induction of OPN and its associated MMPs activities may 
play an important role in the development of VSMC migration, proliferation and 
intimal hyperplasia in vivo. Our observation indicated that OPN might be a novel 
vascular marker involved in the process of vein graft failure. These findings may help 
in developing therapeutic intervention aiming at increasing the expression of an 
endogenous vascular regulator, rather than aggressively inhibiting any isolated step of 
the remodeling process. 
Although the mechanisms involved in vein graft failure is complex, there has 
been several initiatives for better defining these disease processes and for 
interventions to prevent them. It appears that certain treatments prior to vessel 
grafting are able to influence on VSMC migration and proliferation, matrix 
production, as well as other variables associated with vascular remodeling. Such 
inhibitory effects on neointimal hyperplasia could be sustained at three months 
post-grafting. On the basis of the available preclinical data, one can certainly propose 
the initiation of clinical gene therapy trial targeting directly at the graft to prevent the 
development of late vein graft failure. Obviously, even a slight improvement in the 
outcome of CABG operation through the successful prevention of vein graft failure 
would ultimately generate a huge clinical and socioeconomic impact. 
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